Several large trials are currently assessing the efficacy of these antisense oligonucleotide agents for the prevention of CHD.36,37 Volanesorsen lowers ApoC3 (mean decreases >75%), but also reduces ApoC2 and ApoE (mean decreases ~50%) as demonstrated by our MS assay.16 Thus, the availability of new therapeutics for lipid-lowering has also reinforced the need to provide more comprehensive apolipoprotein assays to inform treatment decisions. The gene discussed is APOC3; the disease is coronary artery disorder.